Literature DB >> 18051857

High-level expression of the Hcc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen.

Yun-Zhou Yu1, Zhi-Wei Sun, Shuang Wang, Wei-Yuan Yu.   

Abstract

A completely synthetic gene encoding the He domain of Clostridium botulinum neurotoxin serotype A (AHc, 1287 bp, 429 aa, -50 kD) was constructed with oligonucleotides. After expressed in Escherichia coli, soluble product AHc was gained and verified by SDS-PAGE and Western blot analysis. The expressive level of recombinant AHc in E. coli was very high (36%-53% of soluble total proteins) and the purified yield was more than 30 mg/L by one-step purification. Then, the purified AHc was used to vaccinate Balb/c mice, which developed a strong and specific immune response as expected following administration of AHe protein via the subcutaneous route. Results from BoNT/A neutralization assay showed that the serum from mice vaccinated with AHc contained high titer protective antibody. These results showed that the soluble, stable and high-levelly expressive AHc not only could be produced by the prokaryotic expression system built in our lab, but also owned strong immunogenicity to prepare antitoxin for treatment and as sub-unit candidate vaccine for prophylaxis against botulinum toxin serotype A.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18051857     DOI: 10.1016/s1872-2075(07)60052-1

Source DB:  PubMed          Journal:  Sheng Wu Gong Cheng Xue Bao        ISSN: 1000-3061


  6 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E.

Authors:  Ebrahim Valipour; Mir-Latif Moosavi; Jafar Amani; Shahram Nazarian
Journal:  World J Microbiol Biotechnol       Date:  2014-01-29       Impact factor: 3.312

3.  Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models.

Authors:  Zherong You; Hao Yang; Wenwen Xin; Lin Kang; Shan Gao; Junhong Wang; Tao Zhang; Jinglin Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.

Authors:  Yun-Zhou Yu; Na Li; Rui-Lin Wang; Heng-Qi Zhu; Shuang Wang; Wei-Yuan Yu; Zhi-Wei Sun
Journal:  Clin Vaccine Immunol       Date:  2008-10-08

5.  The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Authors:  Alon Ben David; Eran Diamant; Ada Barnea; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

6.  Immunogenicity evaluation of rBoNT/E nanovaccine after mucosal administration.

Authors:  Mohamad Javad Bagheripour; Firouz Ebrahimi; Abbas Hajizade; Shahram Nazarian
Journal:  Iran J Basic Med Sci       Date:  2019-04       Impact factor: 2.699

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.